TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01467076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized Normal Saline
Description: Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled PGE1
Description: Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled PGE1
Description: Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
Study: NCT01271361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary PCI with thrombectomy
Description: thrombectomy is performed before implantation of a drug eluting stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary PCI without thrombectomy
Description: no thrombectomy is performed before the implantation of a drug eluting stent
Study: NCT02749253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga Tauma Relief Program (SKY).
Description: Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
Study: NCT04148794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: echo-assisted advanced life support
Description: Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes
Study: NCT00990184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: colesevelam HCl 3.75 g once daily orally with the evening meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: tablet (s) orally given with evening meal
Study: NCT02231619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline verbal instruction on LSUPT
Study: NCT04149561

Intervention type: OTHER
Intervention: communication skill measurement with self report questionnaire
Description: Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
Study: NCT03284840

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessement of nutritional status
Description: Nutritional status for vitamin D, folic acid, vitamin B12 and iron.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessement of nutritional status
Description: Nutritional status for vitamin D, folic acid, vitamin B12 and iron.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid size
Description: Thyroid size by ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid size
Description: Thyroid size by ultrasound.
Study: NCT02705885

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lozenges containing IgY
Description: Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IgY
Description: Placebo IgY
Study: NCT02363153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates.
Study: NCT03233997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21018
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21033
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21034
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21035
Description: An electronic cigarette
Study: NCT04306588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are undergoing a 12 weeks tele-rehabilitation program.
Study: NCT02270112

Intervention type: DEVICE
Intervention: ECG
Description: Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
Study: NCT01740024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 (Dose Response Skin Prick Tests)
Description: 3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study: NCT01429701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polymyxin B sulphate + prednisolone + benzocaine + clioquinol
Description: applied 3 times / day at lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone + gentamicin + tolnaftato + cleoquinol
Description: applied 3 times / day at lesion
Study: NCT01989247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management programme
Description: Seven weekly group-based sessions for people with anxiety and depressive symptoms
Study: NCT03161106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose plus diet consumed by patient

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Protein Powder 15 to 20 gm/meal/day
Study: NCT02745808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs
Description: The subjects will receive intracavernous injection of HUCMSC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable Collagen Scaffold + HUC-MSCs
Description: The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
Study: NCT01806909

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ad4-H5-Vtn
Study: NCT01277874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory NCPAP
Description: Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
Study: NCT02184858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril, ACE-inhibitor
Description: Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
Study: NCT01865448

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 DHA
Description: Patients take daily 2 tablets of Docosahexaenoic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in control group take daily 2 placebo capsule
Study: NCT01822418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Description: Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
Study: NCT02625844

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study.
Study: NCT00952081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
Study: NCT04077853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 Hydroxyprogesterone Capronate
Description: Intramuscular injection 250 mg
Study: NCT02291419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: ticagrelor 90 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 81 mg daily
Study: NCT04427020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein + GBI-30
Description: Both conditions matched flavor, color, and serving size

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein
Description: Both conditions matched flavor, color, and serving size
Study: NCT01347931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oxygen Cannula
Description: Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
Study: NCT01874080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin
Study: NCT05257291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Supplementation with 1 mg/day of melatonin for 1 year
Study: NCT04529343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality mediated upper extremity rehabilitation
Description: Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical exercise therapy for upper extremities
Description: All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical exercise therapy for upper extremities
Description: All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
Study: NCT03654508

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ADRB2-genotype guided treatment
Description: This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation
Description: In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
Study: NCT00722956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg once daily, 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: one single dose of 40 mg on day 10
Study: NCT00913445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendicectomy
Description: Wound healing after absorbable and nonabsorbable stitches are compared

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendicectomy
Description: Wound healing after absorbable and nonabsorbable stitches are compared
Study: NCT00708799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin on admission - not enrolled in the RCT
Description: One dose of azithromycin prior to inclusion to the RCT
Study: NCT02290353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEATHERS
Description: FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEATHERS
Description: FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants.
Study: NCT00719680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study: NCT02560272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Minhai-HIB
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Act-HIB®
Description: 0.5ml, intramuscular
Study: NCT03069157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung recruitment maneuver
Description: lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
Study: NCT02905630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: high intensity aerobic interval training
Study: NCT00871338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2197870A
Description: 3 doses given at 2, 3 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar™
Description: 3 co-administered doses, intramuscular into right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: 3 co-administered doses, intramuscular into right thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix™
Description: 1 booster dose at 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix™
Description: 1 booster dose at 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel™
Description: 3 doses given at 2, 3 and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate™
Description: 2 doses given at 3 and 4 months of age
Study: NCT04685265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anle138b
Description: capsule containing excipient and anle138b

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule containing excipient
Study: NCT04137185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone for Injection
Description: rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
Study: NCT04156035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Orally; 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pretreatment
Description: Lamotrigine Placebo
Study: NCT00338325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading program
Description: Reading of children's story/picture books preoperatively
Study: NCT01668498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Study: NCT04156035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pretreatment
Description: Lamotrigine Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Ketamine Placebo
Study: NCT01085370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early psychological intervention
Description: 3 modules: psychoeducation, reconstruction of the trauma, coping skills
Study: NCT02641470

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DA9301 (Vaccinium uliginosum extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02037516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelomyography
Description: quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is used to reverse the effects of neuromuscular blocking agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is used to reverse the effects of neuromuscular blocking agents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Monitor
Description: Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
Study: NCT04091880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine and influenza vaccine
Description: simultaneously administrated with EV71 vaccine and influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: administrated with EV71 vaccine only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: administrated with influenza vaccine only
Study: NCT01668498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Study: NCT02212626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotarex S
Study: NCT00556855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-DO
Description: topical lotion, once daily (evening), total duration: 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical lotion, once daily (evening), total duration: 4 weeks
Study: NCT03696524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tunneled pleural catheter
Description: Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
Study: NCT04207749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID015385 contact lenses
Description: Investigational soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study: NCT04637425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without any active substance.